PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Hypertension. Author manuscript; available in PMC 2010 August 1.
Published in final edited form as:
PMCID: PMC2907155
NIHMSID: NIHMS214151

Failures in Mitochondrial tRNAMet and tRNAGln Metabolism Caused by the Novel 4401A>G Mutation Are Involved in Essential Hypertension in a Han Chinese Family

Abstract

We report here on the clinical, genetic, and molecular characterization of 1 Han Chinese family with maternally transmitted hypertension. Three of 7 matrilineal relatives in this 4-generation family exhibited the variable degree of essential hypertension at the age at onset, ranging from 35 to 60 years old. Sequence analysis of the complete mitochondrial DNA in this pedigree identified the novel homoplasmic 4401A>G mutation localizing at the spacer immediately to the 5′ end of tRNAMet and tRNAGln genes and 39 other variants belonging to the Asian haplogroup C. The 4401A>G mutation was absent in 242 Han Chinese controls. Approximately 30% reductions in the steady-state levels of tRNAMet and tRNAGln were observed in 2 lymphoblastoid cell lines carrying the 4401A>G mutation compared with 2 control cell lines lacking this mutation. Failures in mitochondrial metabolism are apparently a primary contributor to the reduced rate of mitochondrial translation and reductions in the rate of overall respiratory capacity, malate/glutamate-promoted respiration, succinate/glycerol-3-phosphate–promoted respiration, or N,N,N′,N′-tetramethyl-p-phenylenediamine/ascorbate-promoted respiration in lymphoblastoid cell lines carrying the 4401A>G mutation. The homoplasmic form, mild biochemical defect, late onset, and incomplete penetrance of hypertension in this family suggest that the 4401A>G mutation itself is insufficient to produce a clinical phenotype. Thus, the other modifier factors, eg, nuclear modifier genes and environmental and personal factors, may also contribute to the development of hypertension in these subjects carrying this mutation. These data suggest that mitochondrial dysfunctions, caused by the 4401A>G mutation, are involved in the development of hypertension in this Chinese pedigree.

Keywords: hypertension, mitochondria, mutation, tRNA metabolism, maternal inheritance, risk factor, Chinese

Cardiovascular disease is the leading cause of death in America and the world. In particular, hypertension affects ≈1 billion individuals worldwide and 130 million in China.1 The etiology of cardiovascular disease is not well understood because of the multifactorial causes. Cardiovascular disease can be caused by a single gene or multifactorial conditions, resulting from interactions between environment and inherited risk factors. Of hereditary factors, the maternal transmissions of cardiovascular disease have been implicated in some pedigrees, suggesting that the mutation(s) in mitochondrial DNA (mtDNA) is one of the molecular bases for this disorder.26 Recently, several mtDNA point mutations have been identified to be associated with cardiovascular disease. These mutations included the 1555A>G mutation in the 12S ribosomal RNA (rRNA) gene,7 the 3260A>G and 3303C>T mutations in the tRNALeu(UUR) gene,8,9 the 8348A>G and 8363G>A mutations in the tRNALys gene,10,11 and the 4295A>G, 4300A>G, and 4317A>G mutations in the tRNAIle gene.1214 Most recently, the 4291T>C mutation in tRNAIle gene has been associated with a cluster of metabolic defects, including essential hypertension, hypercholesterolemia, and hypomagnesemia in a large family.15

With an effort to understand a role of the mitochondrial genome in the pathogenesis of cardiovascular disease in the Chinese population, we have initiated a systematic and extended mutational screening of mtDNA in a large cohort of hypertension subjects in the Geriatric Cardiology Clinic at the Chinese People’s Liberation Army General Hospital.1618 In the present study, we performed the clinical, genetic, and molecular characterizations of another Han Chinese family with maternally transmitted hypertension. Three (2 men/1 woman) of 7 matrilineal relatives in this 4-generation family exhibited the variable severity and age at onset in hypertension. Mutational analysis of the mitochondrial genome has identified the novel 4401A>G mutation in this Chinese family. This novel 4401A>G mutation is localized at the junction between the tRNAMet at the heavy strand and tRNAGln at the light strand.19,20 Thus, it is hypothesized that the 4401A>G mutation affects the processing of precursors in these mitochondrial tRNAs. Functional significance of the 4401A>G mutation was evaluated by examining for the steady-state levels of mitochondrial tRNAMet, tRNAGln, and other tRNAs, including tRNALys, tRNAGly, and tRNASer-(UCN), using lymphoblastoid cell lines derived from 2 affected matrilineal relatives carrying the 4401A>G mutation and from 2 married-in-control individuals lacking the mtDNA mutation. These cell lines were further assessed for the effects of the 4401A>G mutation on the rate of mitochondrial protein synthesis, the endogenous respiration, and substrate-dependent respiration.

Materials and Methods

Subjects

As a part of genetic screening program for hypertension, a Han Chinese family (Figure 1) was ascertained at the Institute of Geriatric Cardiology of the Chinese People’s Liberation Army General Hospital. Informed consent, blood samples, and clinical evaluations were obtained from all of the participating family members, under protocols approved by ethic committee of the Chinese People’s Liberation Army General Hospital and the Cincinnati Children’s Hospital Medical Center Institute Review Board. Members of this family were interviewed and evaluated to identify both personal or medical histories of hypertension and other clinical abnormalities. The 242 control DNA samples were obtained from a panel of unaffected Han Chinese individuals from the same area.

Figure 1
The Chinese pedigree with hypertension. Affected individuals are indicated by filled symbols. Arrowhead denotes proband.

Measurements of Blood Pressure

Members of this Chinese family underwent a physical examination, laboratory assessment of cardiovascular disease risk factors, and routine electrocardiography. A physician measured the systolic and diastolic blood pressures of subjects using a mercury column sphygmomanometer and a standard protocol. The first and the fifth Korotkoff sounds were taken as indicative of systolic and diastolic blood pressures, respectively. The average of 3 such systolic and diastolic blood pressure readings was taken as the examination blood pressure. Hypertension was defined according to the recommendation of the Sixth Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure.21 and the World Health Organization-International Society of Hypertension22 as a systolic blood pressure of ≥140 mm Hg and/or a diastolic blood pressure of ≥90 mm Hg.

Mutational Analysis of Mitochondrial Genome

Genomic DNA was isolated from whole blood of participants using Puregene DNA Isolation kits (Gentra Systems). The entire mitochondrial genome of the proband II-1 was PCR amplified in 24 overlapping fragments by use of sets of the light-strand and the heavy-strand oligonucleotide primers, as described elsewhere.23 Each fragment was purified and subsequently analyzed by direct sequencing in an ABI 3700 automated DNA sequencer using the Big Dye Terminator Cycle sequencing reaction kit. The resultant sequence data were compared with the revised Cambridge reference sequence (GenBank accession No. NC_001807).24

For the quantification of the 4401A>G mutation, the first PCR segments (903 bp) were amplified using genomic DNA as a template and oligodeoxynucleotides corresponding with mtDNA at positions 3777 to 4679 to rule out the coamplification of possible nuclear pseudogenes.25 Then, the second PCR product (225 bp) was amplified using the first PCR fragment as a template, and oligodeoxynucleotides corresponding with mtDNA at positions 4243 to 4467 and subsequently digested with the restriction enzyme BfaI as the 4401A>G mutation creates the site for this restriction enzyme. Equal amounts of various digested samples were then analyzed by electrophoresis through 7% polyacrylamide gel. The proportions of digested and undigested PCR products were determined by the Image-Quant program after ethidium bromide staining to determine whether 4401A>G mutation is in the homoplasmy in these subjects. The allele frequency of the 4401A>G variant was determined by PCR amplification using the genomic DNA derived from 242 Han Chinese controls and subsequent restriction enzyme analysis of PCR products, as described above.

Mitochondrial tRNA Analysis

Lymphoblastoid cell lines were immortalized by transformation with the Epstein-Barr virus, as described elsewhere.26 Cell lines derived from 1 proband II-1 and her son III-3 carrying the 4401A>G mutation and 2 Chinese married-in controls (II-2 and III-4) lacking this mutation were grown in RPMI 1640 (Invitrogen), supplemented with 10% FBS. Total mitochondrial RNA were obtained using a TOTALLY RNA kit (Ambion) from mitochondria isolated from lymphoblastoid cell lines (≈4.0×108 cells), as described previously.27 Two micrograms of total mitochondrial RNA were electrophoresed through a 10% polyacryl-amide/7 mol/L urea gel in Tris-borate-EDTA buffer (after heating the sample at 65°C for 10 minutes) and then electroblotted onto a positively charged nylon membrane (Roche) for the hybridization analysis with oligodeoxynucleotide probes. For the detection of tRNAMet, tRNAGln, tRNALys, tRNAGly, and tRNASer(UCN), the following nonradioactive digoxigenin (DIG)-labeled oligodeoxynucleotides specific for each RNA were used: 5′-TAGTACGGGAAGGGTATAACC-3′ (tRNAMet); 5′-CTAGGACTATGAGAATCGAA-3′ (tRNAGln); 5′-TCACTGTAAAGAGGTGTTGG-3′ (tRNALys); 5′-TACTCTTTTTTGAATGTTGTC-3′ (tRNAGly); and 5′-CAAGCCAACCCCATGGCCTC-3′ (tRNASer(UCN)).24 DIG-labeled oligodeoxynucleotides were generated by using a DIG Oligonucleotide Tailing Kit (Roche). The hybridization was carried out as detailed elsewhere.28 Quantification of density in each band was made as detailed previously.2830

Analysis of Mitochondrial Protein Synthesis

Pulse labeling of the cell lines for 30 minutes with [35S]methionine-[35S]cysteine in methionine-free DMEM in the presence of emetine, electrophoretic analysis of the translation products, and quantification of radioactivity in the whole-electrophoretic patterns or in individual well-resolved bands was carried out as detailed previously.31

O2 Consumption Measurements

Rates of O2 consumption in intact cells were determined with a YSI 5300 oxygraph (Yellow Springs Instruments) on samples of 1×107 cells in 1.5 mL of special DMEM glucose lacking glucose and supplemented with 10% dialyzed FBS.32 Polarographic analysis of digitonin-permeabilized cells using different respiratory substrates and inhibitors to test the activity of the various respiratory complexes was carried out as detailed previously.33

Results

Clinical Presentation

The proband (II-1) began suffering from hypertension at the age of 60 years. She came to the Geriatric Cardiology Clinic of the Chinese People’s Liberation Army General Hospital for further clinical evaluations at the age of 65 years. Her blood pressure was 180/110 mm Hg. Physical examination, laboratory assessment of cardiovascular disease risk factors, and routine electrocardiography showed no other clinical abnormalities, including diabetes mellitus, vision and hearing impairments, or renal and neurological disorders. Therefore, she exhibited a typical essential hypertension. The family originated from Beijing in northern China, and the majority of family members live in the same area. As shown in Figure 1, this familial history is consistent with a maternal inheritance. None of the offspring of affected fathers had hypertension. Two male matrilineal relatives exhibited hypertension as the sole clinical symptom, whereas other members of this family had normal blood pressure. As shown in Table 1, subject III-3 experienced the hypertension (blood pressure was 140/110 mm Hg) at the age of 36 years, whereas his brother (III-5) had hypertension (blood pressure was 140/95 mm Hg) at the age of 35 years. There is no evidence that any member of this family had any other known cause to account for hypertension. Comprehensive family medical histories of these individuals showed no other clinical abnormalities, including diabetes mellitus, vision and hearing impairments, or renal and neurological disorders.

Table 1
Summary of Clinical Data for Some Members in 1 Han Chinese Family

Mitochondrial DNA Analysis

The maternal transmission of hypertension in this family suggested the mitochondrial involvement and led us to analyze the mitochondrial genome of matrilineal relatives. For this purpose, the DNA fragments spanning the entire mtDNA of the proband II-1 were PCR amplified, and each fragment was purified and subsequently analyzed by direct sequence. As shown in Table 2, the comparison of the resultant sequences with the Cambridge consensus sequence identified a number of nucleoside changes, belonging to the Eastern Asian haplogroup C.34 Of these nucleoside changes, there were 8 polymorphisms in the D-loop region, 2 variants in the 12S rRNA gene, 1 variant in the 16S rRNA gene, 1 novel 4401A>G mutation in the spacer between tRNAMet and tRNAGln genes, 20 silent mutations (1 novel and 19 known), and 8 missense mutations in protein-encoding genes.35 These missense mutations are 5262G>A (264A>T) in the ND2 gene, 8584G>A (20A>T), 8701A>G (59T>A), and 8860A>G (112T>A) in the ATP6 gene, 10398A>G (114T>A) in the ND3 gene, 11447G>A (230V>M) in the ND4 gene, 14318T>C (119N>S) in the ND6 gene, and 15326A>G (194T>A) in the Cytb gene. These variants in rRNAs and polypeptides were further evaluated by phylogenetic analysis of these variants and sequences from other organisms, including mouse,36 bovine,37 and Xenopus laevis.38 None of variants in the polypeptides and rRNAs were highly evolutionarily conserved and implicated to have significantly functional consequence.

Table 2
MtDNA Variants in 1 Han Chinese Subject (II-1) With Hypertension

However, the novel A to G transition at the position 4401 (4401A>G) mutation, as shown in Figure 2, lies at the junction of tRNAMet at the H-strand and tRNAGln at the L-strand.19,20 Here the 5′ end of the flanking sequence is 4401A/AGTAAG in the tRNAMet gene, whereas the 5′ end of the flanking sequence is 4401T/TGAGAT in the tRNAGln gene.39 In fact, the processing of mitochondrial tRNAs requires the precise endonucleolytic cleavage at both 3′ and 5′ ends catalyzed by RNase P and 3′ endonuclease.20,40,41 Thus, the 4401A>G mutation may affect the reaction efficiency of the RNase P involved in tRNAMet and tRNAGln 5′ end metabolism. The 4401A>G mutation was further assessed by phylogenetic analysis of this variant and sequences from mouse, bovine, and X laevis, as well as other 13 primates including Gorilla gorilla, Pan paniscus, Pan troglodytes, Pongo pygmaeus, Pongo abelii, Hylobates lar, Macaca mulatta, Macaca sylvanus, Papio hamadryas, Cebus albifrons, Tarsius bancanus, Nycticebus coucang, and Lemur catta (Genbank). In fact, the adenine at the 4401 position is extraordinarily conserved among these species. To determine whether the 4401A>G mutation is present in homoplasmy, the fragments spanning the tRNAMet and tRNAGln genes were PCR amplified and subsequently digested with BfaI, because the 4401A>G mutation creates the site for this restriction enzyme. As shown in Figure 2C, there was no detectable wild-type DNA in 4 matrilineal relatives, indicating that the 4401A>G mutation was present in homoplasmy in these matrilineal relatives. In addition, this mutation was absent in 242 Han Chinese controls.

Figure 2
Identification and qualification of the 4401A>G mutation in the junction between mitochondrial tRNAMet and tRNAGln genes. A, Partial sequence chromatograms of tRNAMet and tRNAGln genes from an affected individual (III-2) and a married-in control ...

Mitochondrial tRNA Analysis

To examine whether the 4401A>G mutation affects the processing of the precursors in the tRNAMet and tRNAGln, the steady-state levels of the tRNAMet and tRNAGln were determined by isolating total mitochondrial RNA from cell lines derived from 2 affected individuals (II-1 and III-3) carrying the 4401A>G mutation and 2 married-in controls (II-2 and III-4) lacking this mutation in this Chinese family, separating them by a 10% polyacrylamide/7 mol/L urea gel, electroblotting, and hybridizing with a nonradioactive DIG-labeled oligodeoxynucleotide probe specific for tRNAMet and tRNAGln. After stripping the blots, the DIG-labeled oligodeoxynucleotide probes, including tRNAGly and tRNALys as representatives of the whole H-strand transcription unit and tRNASer(UCN) derived from the L-strand transcription unit,19,20 were hybridized with the same blots for normalization purposes.

As shown in Figure 3A, the amounts of tRNAMet and tRNAGln in mutant cells were markedly decreased as compared with those in control cells. For comparison, the average levels of tRNAMet and tRNAGln in various control or mutant cell lines were normalized to the average levels in the same cell line for the tRNAGly, tRNALys, and tRNASer(UCN), respectively. As shown in Figure 3B, the levels of tRNAMet and tRNAGln in the mutant cells were significantly reduced relative to the controls. In particular, the average levels of tRNAMet in the mutant cell lines derived from II-1 and III-3 ranged from ≈71% of controls after normalization to tRNAGly, ≈67% of controls after normalization to tRNALys, to ≈70% of controls after normalization to tRNASer(UCN). Similarly, the average levels of tRNAGln in the mutant cell lines derived from II-1 and III-3 ranged from ≈75% of controls after normalization to tRNAGly, ≈71% of controls after normalization to tRNALys, to ≈70% of controls after normalization to tRNASer(UCN).

Figure 3
Northern blot analysis of mitochondrial tRNA. A, Equal amounts (2 μg) of total mitochondrial RNA from various cell lines were electrophoresed through a denaturing polyacrylamide gel, electroblotted, and hybridized with DIG-labeled oligonucleotide ...

Mitochondrial Protein Synthesis Defect

To examine whether a defect in mitochondrial translation occurred in lymphoblastoid cell lines carrying the 4401A>G mutation, cells derived from 2 affected individuals (II-1 and III-3) carrying the 4401A>G mutation and 2 married-in controls (II-2 and III-4) lacking this mutation in this Chinese family were labeled for 30 minutes with [35S]methionine-[35S]cysteine in methionine-free regular DMEM in the presence of 100 μg/mL of emetine to inhibit cytosolic protein synthesis.31 Figure 4A shows typical electrophoretic patterns of the mitochondrial translation products of the mutant and control cell lines. Patterns of the mtDNA-encoded polypeptides of the cells carrying the 4401A>G mutation were qualitatively identical in terms of electrophoretic mobility of the various polypeptides to those of the control cells and of 143B.TK cells. However, the cell lines carrying the 4401A>G mutation showed a clear tendency toward a decrease in the total rate of labeling of the mitochondrial translation products relative to those of control cell lines. Figure 4B shows a quantification of the results of a large number of labeling experiments and electrophoretic runs, which were carried out by the Image-Quant program of appropriate exposures of the fluorograms and normalization to data obtained for the 143B.TK sample. In fact, the overall rates of labeling of the mitochondrial translation products in the cell lines derived from 2 affected individuals (II-1 and III-3) carrying the 4401A>G mutation were decreased 31.7% and 20.8%, with an average of 26.0% relative to the mean value measured in the control cell lines.

Figure 4
Mitochondrial translation assay. A, Electrophoretic patterns of the mitochondrial translation products of lymphoblastoid cell lines and of 143B.TK cells labeled for 30 minutes with [35S]methionine in the presence of 100 μg/mL of emetine. ...

Respiration Defects in the Cell Lines

The endogenous respiration rates of cell lines derived from 2 affected individuals (II-1 and III-3) carrying the 4401A>G mutation and 2 married-in controls (II-2 and III-4) lacking this mutation in this Chinese family were measured by determining the O2 consumption rate in intact cells, as described previously.32 As shown in Figure 5A, the rate of total O2 consumption in the lymphoblastoid cell lines derived from 2 affected individuals (II-1 and III-3) ranged between ~74.9% and 80.6%, with an average reduction of ~77.8% relative to the mean value measured in the control cell lines.

Figure 5
Respiration assays. A, Average rates of endogenous O2 consumption per cell measured in different cell lines are shown, with error bars representing 2 SEMs. A total of 4 determinations were made on each of lymphoblastoid cell lines. B, Polarographic analysis ...

To investigate which of the enzyme complexes of the respiratory chain was affected in the mutant cell lines, O2 consumption measurements were carried out on digitonin-permeabilized cells using different substrates and inhibitors.33 As shown in Figure 5B, in the cell lines derived from 2 affected individuals, the rate of malate/glutamate-driven respiration, which depends on the activities of reduced nicotinamide-adenine dinucleotide:ubiquinone oxidoreductase (complex I), ubiquinol-cytochrome c reductase (complex III), and cytochrome c oxidase (complex IV), but usually reflects the rate-limiting activity of complex I,33 was very significantly decreased, relative to the average rate in the control cell lines, by 77% to 80% (~78% on average). Similarly, the rate of succinate/glycerol-3-phosphate–driven respiration, which depends on the activities of complexes III and IV but usually reflects the rate-limiting activity of complex III, was significantly affected in the mutant cell lines, relative to the average rate in the control cell lines, by 76% to 81% (~78% on average). Furthermore, the rate of N,N,N′,N′-tetramethyl-p-phenylenediamine/ascorbate-driven respiration, which reflects the activity of complex IV, exhibited a 78% to 82% reduction in complex IV activity (~80% on average) in the mutant cell lines relative to the average rate in the control cell lines.

Discussion

In the present study, we performed the clinical, genetic, and molecular characterization of a Han Chinese family with essential hypertension. The hypertension as a sole clinical phenotype was only present in all of the matrilineal relatives of this 4-generation pedigree. Clinical and genetic evaluations revealed the variable severity and age at onset in hypertension among 3 of 7 matrilineal relatives in this Chinese family. In particular, the age at onset in hypertension was 60, 36, and 35 years in 3 affected matrilineal relatives, with an average age of 44 years. The maternal transmission of hypertension in this family suggested that the mtDNA mutation(s) is 1 of the molecular bases for this disorder. Mutational analysis of the mitochondrial genome in this family identified 40 variants belonging to the Eastern Asian haplogroup C.34 Of these, 39 variants appeared to be polymorphisms, because these variants were not highly evolutionarily conserved and implicated to have significantly functional consequence. However, the homoplasmic A-to-G transition at position 4401 lies in the spacer immediately to the 5′ end of the tRNAMet and tRNAGln genes.19,24 Furthermore, the adenine at the 4401 position of the mitochondrial genomes is highly conserved among various primates. This mutation is present only in matrilineal relatives of this family in the homoplasmic form but not in the 242 Han Chinese controls, indicating that this mutation may be involved in the pathogenesis of hypertension.

In fact, 22 human mitochondrial tRNAs are interspersed among the other functional mitochondrial RNAs (2 rRNAs and 11 mRNAs encoding 13 polypeptide subunits of the oxidative phosphorylation complexes) on long precursor transcripts.19 Of these, 8 tRNAs, including tRNAGln and tRNASer(UCN), are synthesized from the polycistronic precursors of the L-strand, whereas the other 14 tRNAs, eg, tRNAMet, tRNALys, and tRNAGly, are transcribed from the precursors of the H-strand transcripts.19,42 The processing of precursors in mitochondrial tRNAs requires the precise endonucleolytic cleavage at both 5′ and 3′ ends. Extra nucleotides at their 5′ termini are removed by RNase P, whereas the excision of tRNAs from primary polycistronic mitochondrial transcripts at their 3′ end is catalyzed by the 3′ endonucle-ase.19,43 Thus, it is anticipated that the A-to-G transition at position 4401 in the H-strand may lead to defective tRNAMet 5′ end processing in the H-strand transcripts, and the T-to-C transition at position 4401 may cause the reduced efficiency of the tRNAGln precursor 5′ end cleavage in the L-strand transcripts. There is increasing evidence showing that the 5′ and 3′ end processing defects arising from pathogenic mitochondrial tRNA mutations could contribute to clinical abnormalities. The deafness-associated 7445T>C mutation in the precursor of the tRNASer(UCN) gene and the cardiomyopathies-associated 4269A>G and 4295A>G mutations in the tRNAIle gene altered 3′ end processing efficiency of corresponding tRNAs.41,44 Similarly, the mitochondrial encephalomyopathy, lactic acidosis, stroke-like symptoms (MELAS)-associated 3243A>G and 3271T>C mutations and mitochondrial myopathy-associated 3302A>G mutation in the tRNALeu(UUR) led to the tRNA 5′ end processing defects.45,46 Alternatively, a taurine modification deficiency at the anticodon wobble position of tRNALeu(UUR) carrying the 3243A>G or 3271T>C mutation is involved in the decreased translation of ND6 with a high content of the UUG codon.47

In the current study, compared with a control cell lacking the mutation, a ≈30% reduction in the levels of tRNAMet and tRNAGln were observed in cells carrying the 4401A>G mutation. The lower levels of tRNAMet and tRNAGln in cells carrying the 4401A>G mutation most probably result from a defect in the 5′ end processing of tRNAMet and tRNAGln precursors. As a result, a shortage of the tRNAMet and tRNAGln leads to the reduced rate of mitochondrial protein synthesis. These defects appear to be responsible for the reduced activities of the mitochondrial respiration chain. Subsequently, these defects lead to the reduction of ATP production and an increase of reactive oxygen species production. These mitochondrial dysfunctions likely contribute to the development of hypertension.4850 However, the levels of total tRNAMet and tRNAGln in mutant cells are above a proposed threshold, which is 30% of the control level of tRNA, to support a normal rate of mitochondrial translation.20,28 Thus, the homoplasmic form, mild mitochondrial dysfunctions, late onset, and incomplete penetrance of hypertension in this family carrying the 4401A>G mutation indicated that the 4401A>G mutation itself is insufficient to produce a clinical phenotype, as in the cases of hypertension-associated tRNAMet 4435A>G mutation,18 deafness-associated 12S rRNA 1555A>G mutation,51,52 and Leber’s hereditary optic neuropathy–associated ND4 11778G>A mutation.53 The other modifier factors, eg, nuclear modifier genes, environmental factors, and personal lifestyles, also contribute to the development of hypertension in these subjects carrying the 4401A>G mutation. Therefore, the 4401A>G mutation, acting as an inherited risk factor, is involved in the development of hypertension in this Chinese family.

Perspectives

The genetic and biochemical evidence indicate that the mtDNA 4401A>G mutation is involved in essential hypertension. The tissue specificity of this pathogenic mtDNA mutation is likely attributed to tissue-specific RNA processing or the involvement of nuclear modifier genes. The 4401A>G mutation should be added to the list of inherited risk factors for future molecular diagnosis for hypertension. Thus, our finding will provide new insights into the molecular mechanism, management, and treatment of maternally inherited hypertension. Future research should further explore the emerging link among hypertension, mitochondrial dysfunction, and their causative-effect relationship.

Acknowledgments

Sources of Funding

This work was supported by National Institutes of Health grants RO1DC05230 and RO1DC07696 from the National Institute on Deafness and Other Communication Disorders (to M-X.G.) and National Key Basic Research and Development Project 973 Fund 2007CB07403 (to S.W.).

Footnotes

Disclosures

None.

References

1. Gu D, Reynolds K, Wu X, Chen J, Duan X, Muntner P, Huang G, Reynolds RF, Su S, Whelton PK, He J. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension. 2002;40:920–927. [PubMed]
2. Brandao AP, Brandao AA, Araujo EM, Oliveira RC. Familial aggregation of arterial blood pressure and possible genetic influence. Hypertension. 1992;19:II214–II217. [PubMed]
3. Wallace DC. Mitochondrial defects in cardiomyopathy and neuro-muscular disease. Am Heart J. 2000;139:S70–S85. [PubMed]
4. Watson B, Jr, Khan MA, Desmond RA, Bergman S. Mitochondrial DNA mutations in black Americans with hypertension-associated end-stage renal disease. Am J Kidney Dis. 2001;38:529–536. [PubMed]
5. Hirano M, Davidson M, DiMauro S. Mitochondria and the heart. Curr Opin Cardiol. 2001;16:201–210. [PubMed]
6. Schwartz F, Duka A, Sun F, Cui J, Manolis A, Gavras H. Mitochondrial genome mutations in hypertensive individuals. Am J Hypertens. 2004;17:629–635. [PubMed]
7. Santorelli FM, Tanji K, Manta P, Casali C, Krishna S, Hays AP, Mancini DM, DiMauro S, Hirano M. Maternally inherited cardiomyopathy: an atypical presentation of the mtDNA 12S rRNA gene A1555G mutation. Am J Hum Genet. 1999;64:295–300. [PubMed]
8. Zeviani M, Gellera C, Antozzi C, Rimoldi M, Morandi L, Villani F, Tiranti V, DiDonato S. Maternally inherited myopathy and cardiomyopathy: association with mutation in mitochondrial DNA tRNALeu(UUR) Lancet. 1991;338:143–147. [PubMed]
9. Silvestri G, Santorelli FM, Shanske S, Whitley CB, Schimmenti LA, Smith SA, DiMauro S. A new mtDNA mutation in the tRNALeu(UUR) gene associated with maternally inherited cardiomyopathy. Hum Mut. 1994;3:37–43. [PubMed]
10. Santorelli FM, Mak SC, El-Schahawi M, Casali C, Shanske S, Baram TZ, Madrid RE, DiMauro S. Maternally inherited cardiomyopathy and hearing loss associated with a novel mutation in the mitochondrial tRNALys gene (G8363A) Am J Hum Genet. 1996;58:933–939. [PubMed]
11. Terasaki F, Tanaka M, Kawamura K, Kanzaki Y, Okabe M, Hayashi T, Shimomura H, Ito T, Suwa M, Gong JS, Zhang J, Kitaura Y. A case of cardiomyopathy showing progression from the hypertrophic to the dilated form: association of Mt8348A–>G mutation in the mitochondrial tRNALys gene with severe ultrastructural alterations of mitochondria in cardiomyocytes. Jpn Circ J. 2001;65:691–694. [PubMed]
12. Merante F, Myint T, Tein I, Benson L, Robinson BH. An additional mitochondrial tRNAIle point mutation (A-to-G at nucleotide 4295) causing hypertrophic cardiomyopathy. Hum Mut. 1996;8:216–222. [PubMed]
13. Taylor RW, Giordano C, Davidson MM, d’Amati G, Bain H, Hayes CM, Leonard H, Barron MJ, Casali C, Santorelli FM, Hirano M, Lightowlers RN, DiMauro S, Turnbull DM. A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41:1786–1796. [PubMed]
14. Tanaka M, Ino H, Ohno K, Hattori K, Sato W, Ozawa T, Tanaka T, Itoyama S. Mitochondrial mutation in fatal infantile cardiomyopathy. Lancet. 1990;336:1452. [PubMed]
15. Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science. 2004;306:1190–1194. [PubMed]
16. Li Z, Liu Y, Yang L, Wang S, Guan MX. Maternally inherited hypertension is associated with the mitochondrial tRNAIle A4295G mutation in a Chinese family. Biochem Biophys Res Commun. 2008;367:906–911. [PubMed]
17. Liu Y, Li Z, Yang L, Wang S, Guan MX. The mitochondrial ND1 T3308C mutation in a Chinese family with the secondary hypertension. Biochem Biophys Res Commun. 2008;368:18–22. [PubMed]
18. Liu Y, Li R, Li Z, Wang X, Yang L, Wang S, Guan MX. The mitochondrial transfer RNAMet 4435A>G mutation is associated with maternally hypertension in a Chinese pedigree. Hypertension. 2009;53:1083–1090. [PMC free article] [PubMed]
19. Ojala D, Montoya J, Attardi G. tRNA punctuation model of RNA processing in human mitochondria. Nature. 1981;290:470–474. [PubMed]
20. Guan MX, Enriquez JA, Fischel-Ghodsian N, Puranam R, Lin CP, Marion MA, Attardi G. The deafness-associated mtDNA 7445 mutation, which affects tRNASer(UCN) precursor processing, has long-range effects on NADH dehydrogenase ND6 subunit gene expression. Mol Cell Biol. 1998;18:5868–5879. [PMC free article] [PubMed]
21. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151–183. [PubMed]
22. Joint national Committee on Prevention, Detection, Evaluation and Treatment of High Blood pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413–2446. [PubMed]
23. Rieder MJ, Taylor SL, Tobe VO, Nickerson DA. Automating the identification of DNA variations using quality-based fluorescence re-sequencing: analysis of the human mitochondrial genome. Nucleic Acids Res. 1998;26:967–973. [PMC free article] [PubMed]
24. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet. 1999;23:147. [PubMed]
25. Woischnik M, Moraes CT. Pattern of organization of human mitochondrial pseudogenes in the nuclear genome. Genome Res. 2002;12:885–893. [PubMed]
26. Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A. 1973;70:190–194. [PubMed]
27. King MP, Attardi G. Post-transcriptional regulation of the steady-state levels of mitochondrial tRNAs in HeLa cells. J Biol Chem. 1993;1268:10228–10237. [PubMed]
28. Li X, Fischel-Ghodsian N, Schwartz F, Yan Q, Friedman RA, Guan MX. Biochemical characterization of the mitochondrial tRNASer(UCN) T7511C mutation associated with nonsyndromic deafness. Nucleic Acids Res. 2004;32:867–877. [PMC free article] [PubMed]
29. Guan MX, Yan Q, Li X, Bykhovskaya Y, Gallo-Teran J, Hajek P, Umeda N, Zhao H, Garrido G, Mengesha E, Suzuki T, del Castillo I, Peters JL, Li R, Qian Y, Wang X, Ballana E, Shohat M, Lu J, Estivill X, Watanabe K, Fischel-Ghodsian N. Mutation in TRMU related to transfer RNA modification modulates the phenotypic expression of the deafness-associated mitochondrial 12S ribosomal RNA mutations. Am J Hum Genet. 2006;79:291–302. [PubMed]
30. Wang X, Lu J, Zhu Y, Yang A, Yang L, Li R, Chen B, Qian Y, Tang X, Wang J, Zhang X, Guan MX. Mitochondrial tRNAThr G15927A mutation may modulate the phenotypic manifestation of ototoxic 12S rRNA A1555G mutation in four Chinese families. Pharmacogenet Genomics. 2008;18:1059–1070. [PMC free article] [PubMed]
31. Chomyn A. In vivo labeling and analysis of human mitochondrial translation products. Methods Enzymol. 1996;264:197–211. [PubMed]
32. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 1989;246:500–503. [PubMed]
33. Hofhaus G, Shakeley RM, Attardi G. Use of polarography to detect respiration defects in cell cultures. Methods Enzymol. 1996;264:476–483. [PubMed]
34. Tanaka M, Cabrera VM, Gonzalez AM, Larruga JM, Takeyasu T, Fuku N, Guo LJ, Hirose R, Fujita Y, Kurata M, Shinoda K, Umetsu K, Yamada Y, Oshida Y, Sato Y, Hattori N, Mizuno Y, Arai Y, Hirose N, Ohta S, Ogawa O, Tanaka Y, Kawamori R, Shamoto-Nagai M, Maruyama W, Shimokata H, Suzuki R, Shimodaira H. Mitochondrial genome variation in eastern Asia and the peopling of Japan. Genome Res. 2004;84:1832–1850. [PubMed]
35. Brandon MC, Lott MT, Nguyen KC, Spolim S, Navathe SB, Baldi P, Wallace DC. MITOMAP: a human mitochondrial genome database–2004 update. Nucleic Acids Res. 2005;33:D611–D613. [PMC free article] [PubMed]
36. Bibb MJ, Van Etten RA, Wright CT, Walberg MW, Clayton DA. Sequence and gene organization of mouse mitochondrial DNA. Cell. 1981;26:167–180. [PubMed]
37. Gadaleta G, Pepe G, De Candia G, Quagliariello C, Sbisa E, Saccone C. The complete nucleotide sequence of the Rattus norvegicus mitochondrial genome: cryptic signals revealed by comparative analysis between vertebrates. J Mol Evol. 1989;28:497–516. [PubMed]
38. Roe A, Ma DP, Wilson RK, Wong JF. The complete nucleotide sequence of the Xenopus laevis mitochondrial genome. J Biol Chem. 1985;260:9759–9774. [PubMed]
39. Florentz C, Sohm B, Tryoen-Toth P, Putz J, Sissler M. Human mitochondrial tRNAs in health and disease. Cell Mol Life Sci. 2003;60:1356–1375. [PubMed]
40. Holzmann J, Frank P, Löffler E, Bennett KL, Gerner C, Rossmanith W. RNase P without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme. Cell. 2008;135:462–474. [PubMed]
41. Levinger L, Jacobs O, James M. In vitro 3′-end endonucleolytic processing defect in a human mitochondrial tRNASer(UCN) precursor with the U7445C substitution, which causes nonsyndromic deafness. Nucleic Acids Res. 2001;29:4334–4340. [PMC free article] [PubMed]
42. Montoya J, Ojala D, Attardi G. Distinctive features of the 5′-terminal sequences of the human mitochondrial mRNAs. Nature. 1981;290:465–470. [PubMed]
43. Levinger L, Mörl M, Florentz C. Mitochondrial tRNA 3′ end metabolism and human disease. Nucleic Acids Res. 2004;32:5430–5441. [PMC free article] [PubMed]
44. Levinger L, Giegé R, Florentz C. Pathology-related substitutions in human mitochondrial tRNAIle reduce precursor 3′ end processing efficiency in vitro. Nucleic Acids Res. 2003;31:1904–1192. [PMC free article] [PubMed]
45. Bindoff LA, Howell N, Poulton J, McCullough DA, Morten KJ, Lightowlers RN, Turnbull DM, Weber K. Abnormal RNA processing associated with a novel tRNA mutation in mitochondrial DNA: a potential disease mechanism. J Biol Chem. 1993;268:19559–19564. [PubMed]
46. Rossmanith W, Karwan RM. Impairment of tRNA processing by point mutations in mitochondrial tRNALeu(UUR) associated with mitochondrial diseases. FEBS Lett. 1998;433:269–274. [PubMed]
47. Kirino Y, Yasukawa T, Ohta S, Akira S, Ishihara K, Watanabe K, Suzuki T. Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease. Proc Natl Acad Sci U S A. 2004;101:15070–150705. [PubMed]
48. Postnov YV, Orlov SN, Budnikov YY, Doroschuk AD, Postnov AY. Mitochondrial energy conversion disturbance with decrease in ATP production as a source of systemic arterial hypertension. Pathophysiology. 2007;14:195–204. [PubMed]
49. Lopez-Campistrous A, Hao L, Xiang W, Ton D, Semchuk P, Sander J, Ellison MJ, Fernandez-Patron C. Mitochondrial dysfunction in the hypertensive rat brain: respiratory complexes exhibit assembly defects in hypertension. Hypertension. 2008;51:412–4129. [PubMed]
50. Addabbo F, Montagnani M, Goligorsky MS. Mitochondria and reactive oxygen species. Hypertension. 2009;53:885–892. [PMC free article] [PubMed]
51. Tang X, Yang L, Zhu Y, Liao Z, Wang J, Qian Y, Tao Z, Hu L, Wu G, Lan J, Wang X, Ji J, Wu J, Ji Y, Feng J, Chen J, Li Z, Zhang X, Lu J, Guan MX. Very low penetrance of hearing loss in seven Han Chinese pedigrees carrying the deafness-associated 12S rRNA A1555G mutation. Gene. 2007;393:11–19. [PubMed]
52. Guan MX, Fischel-Ghodsian N, Attardi G. Nuclear background determines biochemical phenotype in the deafness-associated mitochondrial 12S rRNA mutation. Hum Mol Genet. 2001;10:573–580. [PubMed]
53. Qu J, Zhou X, Zhang J, Zhao F, Sun YH, Yong Y, Wei QP, Cai W, West CE, Guan MX. Extremely low penetrance of Leber’s hereditary optic neuropathy (LHON) in eight Han Chinese families carrying the ND4 G11778A mutation. Ophthalmology. 2009;116:558–564. [PMC free article] [PubMed]